Skip to main content
. 2014 Sep 10;37(10):2668–2676. doi: 10.2337/dc14-0817

Figure 2.

Figure 2

Cumulative diabetes incidence in the DREAM study, where subjects with prediabetes were given rosiglitazone or placebo, including time points before and after the primary study was stopped (vertical dashed line). Adapted with permission from Gerstein et al. (32).